326-91-0Relevant articles and documents
Studies on the adsorption and photocatalytic degradation of an EuIII(TTFA)3(MePhTerpy) complex on the TiO2 surface
Melchers, Stephanie,Alsalka, Yamen,Schneider, Jenny,Bahnemann, Detlef W.
, p. 303 - 308 (2018)
The luminescent dye EuropiumIII(thenoyltrifluoroacetone)(4′-(4-methylphenyl)-2,2′:6′,2′′-terpyridine) (EuIII(TTFA)3(MePhTerpy)) has been proposed as a probe molecule for a fast photocatalytic test of TiO2-materials. For an industrial application of this test method the underlying photocatalytic reaction mechanism and the degradation products of the dye need to be known. Hence, in this study the adsorption and the photocatalytic degradation of the luminescent dye on the TiO2 surface were investigated by means of ATR-FTIR spectroscopy and GC/MS analysis. The dye is adsorbed by the thenoyltrifluoroacetone (TTFA) ligand on the TiO2 surface as evinced by the respective ATR-FTIR spectra. It is assumed that TTFA and TiO2 form hydrogen bonds. Upon UV illumination the ATR-FTIR spectra reveal a degradation of the TTFA ligand forming trifluoroacetic acid (TFAA) and 2-thiophenecarboxylic acid (TCA). GC/MS analysis confirms the ATR-FTIR results because TCA and TFAA are also detected here. Additionally, 2-thiophenecarboxaldehyde is observed, which is proposed to be an intermediate that is further oxidized to TCA.
Discovery and structure-resistance relationship study of new thieno[2,3-b] pyridine HCV NS4B inhibitors
Xiao, Kun-Jie,Zuo, Wei-Qiong,Xu, Ying,Tao, Xin,Yu, Luo-Ting,Wang, Ning-Yu
, p. 321 - 325 (2019/08/22)
The non-structural protein 4B (NS4B) of hepatitis C virus (HCV) has emerged as a promising target for chronic hepatitis C treatment. The thieno[2,3-b]pyridine HCV inhibitor 2 has demonstrated properties as a NS4B inhibitor. Subsequent hybridization of 2 with our recently published imidazo[2,1-b]thiazole NS4B inhibitor 3 resulted in the discovery of several more potent compounds with sub-micromolar EC50 against HCV genotype 1b replicon. More importantly, the resistant profile study of the new synthesized HCV inhibitors illustrated that the bicyclic scaffold would mediate the resistance of H3R and Q26R mutations, while the piperazinone motif would mediate the resistance of H94R, F98C and V105M mutations, and the C3- amino group would disrupt the interaction between piperazinone motif and NS4B. This structure-resistance relationship detail could help us to develop new NS4B inhibitors with higher resistant barrier in the future.
Design and synthesis of novel benzenesulfonamide containing 1,2,3-triazoles as potent human carbonic anhydrase isoforms I, II, IV and IX inhibitors
Kumar, Rajiv,Vats, Lalit,Bua, Silvia,Supuran, Claudiu T.,Sharma, Pawan K.
, p. 545 - 551 (2018/06/18)
In a quest to discover new biologically active compounds, a series of twenty novel heterocyclic derivatives substituted at position 5 with -H (7a-7j) or -CF3 (8a-8j), bearing benzenesulfonamide at N-1 position and various aroyl groups at position 4 of the 1,2,3-triazole ring was synthesized and screened for their carbonic anhydrase (CA, EC 4.2.1.1) inhibition potential against four human (h) isoforms hCA I, II, IV and IX. All the compounds (7a-7j and 8a-8j) were synthesized via [3+2] cycloaddition reaction from 4-azidobenzenesulfonamide. Interestingly, compounds 7a-7j were prepared in one pot manner via enaminone intermediate using novel methodology. All the newly synthesized compounds (7a-7j & 8a-8j) were found to be excellent inhibitors of edema related isoform hCA I with their inhibition constant (Ki) ranging from 30.1 to 86.8 nM as compared to standard drug acetazolamide (AAZ) with Ki = 250 nM. Further it was found that most of tested compounds were weaker inhibitors of isoform, hCA II although compounds 7b, 7d-7e, 8a, 8d-8f, 8i (mostly with electron withdrawing substituents) have shown better inhibition potential (Ki i = 52.4 nM) than AAZ (Ki = 74 nM) while against tumor associated hCA IX, all the compounds have shown moderate inhibition potential. Present study have added one more step in exploring the 1,2,3-triazlole moiety in the medicinal field.